Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct 15:2012:267643.
doi: 10.5402/2012/267643. eCollection 2012.

Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy

Affiliations

Triamcinolone and bevacizumab as adjunctive therapies to panretinal photocoagulation for proliferative diabetic retinopathy

F Lopez-Lopez et al. ISRN Ophthalmol. .

Abstract

Purpose. To evaluate efficacy of intravitreal triamcinolone (IVT) and bevacizumab (IVB) as adjunctive treatments to panretinal photocoagulation (PRP) in proliferative diabetic retinopathy (PDR). Methods. In 60 eyes of 45 patients with PDR, PRP (PRP group), PRP with IVT (IVT group), or PRP with IVB (IVB group) was performed. Regression of new vessels (NV), changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and contrast sensitivity at 1,2, and 6 months were evaluated. Results. Initial mean numbers of active NV and BCVA were 3.45 and 67.35 in the PRP group, 4.35 and 76.65 in the IVT group, and 4.79 and 75.53 in the IVB group. At the 6-month follow-up, numbers of active NV were 2.5 (P = 0.064), 1.11 (P = 0.000), and 1.11 (P = 0.002), and there was a mean loss of 2,6 (P = 0.055), 3.9 (P = 0.011), and 0.9 letters (P = 0.628) in the PRP, IVT, and IVB groups, respectively. Changes in CMT in the PRP and IVT groups were not significant, but significantly increased in the IVB group (P = 0.032). Contrast sensitivity remained stable in PRP and IVB groups and slightly decreased in IVT group. Conclusions. Adjunctive use of both triamcinolone and bevacizumab with PRP lead to a greater reduction of active NV than PRP alone in PDR, although no differences were seen between the two of them.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(a) Changes in the activity of the new vessels in the three groups during the follow-up period, based on the diffusion observed on fluorescein angiography. (b) Changes in the visual acuity (number of ETDRS letters) in the three groups during the follow-up period. (c) Changes in the central macular thickness (microns) in the three groups after treatments. (d) Changes in the contrast sensitivity (Pelli-Robson score) in the three groups during the follow-up period. (e) Intraocular pressure changes (mmHg) in the three groups during the follow-up period. The Student's t-test was used to compare the changes in the outcomes to the baseline values for the three groups. *P  value < 0.05 and **P  value < 0.10.

References

    1. Kempen J, O'Colmain B, Leske M. The prevalence of diabetic retinopathy among adults in the United States. Archives of Ophthalmology. 2004;122:p. 12. - PubMed
    1. Klein R, Klein BEK, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Archives of Ophthalmology. 1984;102(4):520–526. - PubMed
    1. Klein R, Klein BEK, Moss SE. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Archives of Ophthalmology. 1984;102(4):527–532. - PubMed
    1. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. American Journal of Ophthalmology. 1994;118(4):445–450. - PubMed
    1. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine. 1994;331(22):1480–1487. - PubMed

LinkOut - more resources